jcm-logo

Journal Browser

Journal Browser

Advances in Arrhythmia Diagnosis and Management

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 26 February 2026 | Viewed by 3612

Special Issue Editor


E-Mail Website
Guest Editor
Division of Cardiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032 Debrecen, Hungary
Interests: catheter ablation of supreventricular tachycardias and atrial fibrillation; atrial fibrillation and heart failure; biomarkers in atrial fibrillation; resynchronization therapy; autonomic tests in heart failure; conduction system pacing

Special Issue Information

Dear Colleagues, 

Even though clinical cardiac electrophysiology has experienced marked change throughout the last few decades, it still represents a rapidly evoling field in the modern day. The results of ongoing research and developments in diagnostic and therapeutic approaches including non-pharmacological interventions are being introduced into routine clinical practice to improve quality of life or life expectancy in patients with brady- or tachyarrhythmias.

This Special Issue, “Advances in Arrhythmia Diagnosis and Management”, will focus on recent findings and concepts regarding the diagnosis and treatment of cardiac arrhythmias, including, but not limited to, technical developments and new targets for catheter ablation and device therapy (pacing for bradycardias, ICD, cardiac resynchronization and conduction system pacing) and novel or controversial concepts like population screening and anticoagulation for subclinical atrial fibrillation. Papers summarizing the current state of knowledge, as well as original research, are welcome. Although the focus is on clinical issues, translational research providing new insights and ideas for clinical pratice will also be considered.

Prof. Dr. Zoltán Csanádi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • catheter ablation
  • atrial fibrillation
  • ventricular tachycardia
  • conduction system pacing
  • cardiac resynchronization
  • sudden cardiac death

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

16 pages, 1982 KB  
Article
Head-to-Head Comparison of Single- Versus Dual-Chamber ICD Discriminators for Tachyarrhythmia Detection: A Single-Manufacturer, Remote Monitoring-Based Bicentric Study
by Flora Diana Gausz, Daniel Fodor, Mirjam Turani, Marton Miklos, Attila Benak, Dora Kranyak, Attila Makai, Gabor Bencsik, Peter Bogyi, Robert Pap, Laszlo Saghy, Attila Nemes, Tamas Szili-Torok, Gabor Zoltan Duray and Mate Vamos
J. Clin. Med. 2025, 14(16), 5859; https://doi.org/10.3390/jcm14165859 - 19 Aug 2025
Viewed by 463
Abstract
Background: Modern implantable cardioverter-defibrillators (ICDs) utilize single-chamber (SC) or dual-chamber (DC) discrimination algorithms to differentiate between tachyarrhythmias and minimize the risk of inappropriate therapies. While modern SC algorithms, especially those with morphology detection, are considered comparable to DC algorithms, the available data [...] Read more.
Background: Modern implantable cardioverter-defibrillators (ICDs) utilize single-chamber (SC) or dual-chamber (DC) discrimination algorithms to differentiate between tachyarrhythmias and minimize the risk of inappropriate therapies. While modern SC algorithms, especially those with morphology detection, are considered comparable to DC algorithms, the available data are limited. We aimed to compare the efficacy of SC and DC discrimination algorithms in malignant tachyarrhythmias. Methods: We retrospectively analyzed data from all patients with ICDs from a single manufacturer (Biotronik, Berlin, Germany) who were remotely monitored and followed up at two tertiary centers. Patients were divided into SC and DC groups, based on the programmed discrimination algorithm. The primary outcome was the risk of inappropriate therapies comparing SC vs. DC discriminators. A sensitivity analysis was also conducted, including only a subgroup of SC patients with active morphology discrimination. Results: A total of 557 patients were included. The distribution of the implanted ICDs was as follows: 76 VVI; 226 VDD; 76 DDD; and 179 CRT-D devices. A total of 124 ICDs were programmed utilizing SC and 433 were programmed into the DC discriminators group. Among the SC group, 47 (39%) ICDs used active morphology discrimination. The incidence of inappropriate ICD therapies did not differ among the SC and DC discrimination groups (Hazard Ratio [HR] 1.165; 95% Confidence Interval [CI] 0.393–3.448; p = 0.783). The predefined sensitivity analysis did not reveal any significant difference regarding this outcome (HR 1.809; 95% CI 0.241–13.577; p = 0.564). Conclusions: In this bicentric, remote monitoring-based study, the risk of inappropriate therapy in the SC group was similar to that of the DC group. Based on our results, SC discrimination is a suitable option, even for patients with dual-chamber devices. Full article
(This article belongs to the Special Issue Advances in Arrhythmia Diagnosis and Management)
Show Figures

Figure 1

12 pages, 382 KB  
Article
Association Between Psychosocial Stress and Premature Ventricular Contractions During the Recovery Phase Following Treadmill Testing in Asymptomatic Individuals
by João Paulo de Almeida Dourado, Luan Morais Azevêdo, Larissa de Almeida Dourado, Jaciara Gomes de Oliveira, Bianca Barros de Faria, Karolyne de Oliveira Matos, Leonardo Roever, Paulo Magno Martins Dourado and Pedro Gabriel Senger Braga
J. Clin. Med. 2025, 14(13), 4637; https://doi.org/10.3390/jcm14134637 - 30 Jun 2025
Cited by 1 | Viewed by 756
Abstract
Introduction: Ventricular arrhythmias may lead to sudden cardiac death and, when occurring during the recovery phase after exercise testing, are associated with increased cardiovascular risk. Aim: To investigate the association between psychosocial stress and the risk of premature ventricular contractions (PVCs) during [...] Read more.
Introduction: Ventricular arrhythmias may lead to sudden cardiac death and, when occurring during the recovery phase after exercise testing, are associated with increased cardiovascular risk. Aim: To investigate the association between psychosocial stress and the risk of premature ventricular contractions (PVCs) during the recovery phase after treadmill testing in asymptomatic individuals. Methods: A total of 282 asymptomatic adults underwent treadmill testing. Participants were categorized into a stress-present group (+S, n = 176) or a stress-absent group (−S, n = 106) based on their self-reported psychosocial stress levels. Inclusion criteria included exercising for at least 6 min and reaching at least 85% of the age-predicted maximum heart rate. Exclusion criteria comprised pre-exercise VAs, unreadable ECGs, chronic medication use, systolic blood pressure ≥180 mmHg, and diastolic blood pressure ≥110 mmHg. This study was registered on ClinicalTrials.gov (NCT05987891). Results: Compared to the −S group, the +S group had a higher body mass index (BMI) (p = 0.0025); 26.5 (23.9; 29.0) and larger waist circumference (p = 0.0001); 95 (86; 103), and reported lower physical activity levels (p = 0.0004). Notably, only psychosocial stress and BMI were statistically associated with PVCs during the recovery phase, immediately following the stress test. For each 1 kg/m2 increase in BMI, the risk of PVCs decreased by 9%. Participants reporting psychosocial stress had a 9.03-fold higher risk of PVCs compared to those who did not report stress. Conclusions: Self-reported psychosocial stress significantly increases the risk of PVC occurrence during the recovery phase of treadmill exercise testing in asymptomatic individuals. These findings may support the development of improved PVC detection strategies and enhance cardiovascular risk assessment in clinical settings. Full article
(This article belongs to the Special Issue Advances in Arrhythmia Diagnosis and Management)
Show Figures

Figure 1

Other

Jump to: Research

18 pages, 1822 KB  
Systematic Review
Enhancing Heart Failure Management: A Systematic Review and Meta-Analysis of Continuous Remote Telemedical Management vs. In-Person Visit in Patients with Cardiac Implantable Electronic Devices
by Boglarka Veres, Boldizsar Kiss, Peter Fehervari, Marie Anne Engh, Peter Hegyi, Endre Zima, Bela Merkely and Annamaria Kosztin
J. Clin. Med. 2025, 14(12), 4278; https://doi.org/10.3390/jcm14124278 - 16 Jun 2025
Viewed by 1069
Abstract
Background/Objectives: Remote telemedical management (RTM) in heart failure (HF) patients with cardiac implantable electronic devices (CIED) is a reliable approach to follow device-specific and heart failure-related parameters. However, while some positive outcome data is available, results are inconclusive. We aimed to assess the [...] Read more.
Background/Objectives: Remote telemedical management (RTM) in heart failure (HF) patients with cardiac implantable electronic devices (CIED) is a reliable approach to follow device-specific and heart failure-related parameters. However, while some positive outcome data is available, results are inconclusive. We aimed to assess the benefits of continuous remote telemonitoring (RTM) compared to the in-person visit (IPV) in reducing all-cause mortality, heart failure hospitalizations (HFH), cardiovascular (CV) deaths, and the occurrence of inappropriate therapy. Methods: The study comprised a systematic review and meta-analysis of randomized controlled trials (RCTs) testing RTM (device-related or other non-invasive telemonitoring systems) vs. IPV for the management of HF patients. The main endpoints were all-cause and CV mortality. Risk of bias and level of evidence were assessed. Hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (CI) were calculated. CENTRAL, EMBASE and MEDLINE were searched, and only randomized controlled studies were included. Results: Sixteen RCTs were identified, comprising a total of 11,232 enrolled patients. Seven studies evaluated all-cause mortality, resulting in an OR 0.83 (95% CI 0.72 to 0.96). When CV mortality was assessed, the RTM group showed a significant benefit compared to the IPV group (OR 0.81, 95% CI 0.67 to 0.97). The risk of bias ranged from “low” to “some concerns” for most outcomes, and the certainty was low to moderate depending on the specific outcomes. Conclusions: RTM proved to be superior in reducing all-cause and CV mortality compared to IPV; however, there is a clear need to have standardized alert actions to achieve the mortality benefit. Full article
(This article belongs to the Special Issue Advances in Arrhythmia Diagnosis and Management)
Show Figures

Graphical abstract

12 pages, 1508 KB  
Systematic Review
Efficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials
by Mayank Jha, David Song, Andrew Kung, Sam Lo, Alexander Sacher, Song P. Ang, Aasim Akthar, Hritvik Jain, Raheel Ahmed, Matthew Bates, Sang Lee and Seth Goldbarg
J. Clin. Med. 2025, 14(11), 3720; https://doi.org/10.3390/jcm14113720 - 26 May 2025
Viewed by 908
Abstract
Background: Patients with arrhythmias, particularly paroxysmal supraventricular tachycardia (PSVT), face an increased risk of cardiac complications. Currently, non-parenteral medications for rapid PSVT cessation are lacking. Etripamil, a novel intranasal, short-acting calcium channel blocker, offers a rapid onset and the potential for unsupervised PSVT [...] Read more.
Background: Patients with arrhythmias, particularly paroxysmal supraventricular tachycardia (PSVT), face an increased risk of cardiac complications. Currently, non-parenteral medications for rapid PSVT cessation are lacking. Etripamil, a novel intranasal, short-acting calcium channel blocker, offers a rapid onset and the potential for unsupervised PSVT management. However, data on its use in arrhythmia management remain limited. Aims: We aimed to assess the efficacy and safety of 70 mg of etripamil compared with placebo in the treatment of PSVT. Methods: We systematically searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library for randomized controlled trials (RCTs) from inception to April 2025. We calculated pooled risk ratios (RRs) with 95% confidence intervals (CIs) using random or common effects models, depending on the heterogeneity. Results: Four RCTs including 540 patients were analyzed. Etripamil demonstrated higher conversion rates to the sinus rhythm at 15 min (RR 1.84 [95% CI: 1.32–2.48]), 30 min (RR 1.80 [95% CI: 1.38–2.35]), and 60 min (RR 1.24 [95% CI: 1.04–1.48]). PSVT recurrence rates were similar between groups (RR 0.52 [95% CI: 0.20–1.34]). Adverse events (AEs) and severe AEs were comparable between etripamil and the placebo. Etripamil was associated with higher rates of nasal discomfort, nasal congestion, rhinorrhea, and epistaxis but not with increased bradyarrhythmia, atrial fibrillation, or non-sustained ventricular tachycardia. Conclusions: Etripamil appears to be a promising treatment for cardiac arrhythmias. Larger long-term RCTs are needed to confirm its safety and efficacy in clinical practice. Full article
(This article belongs to the Special Issue Advances in Arrhythmia Diagnosis and Management)
Show Figures

Graphical abstract

Back to TopTop